Anti-CD20s effective MS therapy switch from Tysabri: Review
Switching to one of the anti-CD20 targeting therapies Ocrevus (ocrelizumab) or rituximab may be an effective strategy for discontinuing Tysabri (natalizumab) treatment inĀ multiple sclerosis (MS) patients at risk for progressive multifocal leukoencephalopathy (PML), according to a systematic review. The study, āSwitching from natalizumab to an…